Behavioral and Neuropathological Consequences of Chronic Exposure to Low Doses of the Dopaminergic Neurotoxin MPTP

  • J. S. Schneider


This chapter will discuss the consequences of exposure to the neurotoxin MPTP in nonhuman primates, and particularly the consequences of chronic exposure to low doses of this toxin. Before such a discussion can proceed, some background material about MPTP, its effects on the central nervous system, and the clinical manifestations of these effects needs to be presented.


Caudate Nucleus Attention Deficit Disorder Normal Monkey Object Retrieval Nigrostriatal Dopamine System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander, G.E., DeLong, M.R., and Strick, P.L., 1986, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Ann. Rev. Neurosci. 9:357–381.PubMedCrossRefGoogle Scholar
  2. Arnsten, A.F.T., and Goldman-Rakic, P.S., 1985, Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged non-human primates, Science 230:1273–1276.PubMedCrossRefGoogle Scholar
  3. Ballard, P.A., Tetrud, J.W., and Langston, J.W., 1985, Permanent human parkinsonism due to 1-methyl-4-phenyl-l,2,3,6tetrahydropyridine (MPTP): Seven cases, Neurology 35:949–956.PubMedCrossRefGoogle Scholar
  4. Battig, K., Rosvold, H.E., and Mishkin, M., 1960, Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys, J. Comp. Psycho!. 53:400–404.CrossRefGoogle Scholar
  5. Boyce, S., Rupniak, N.M.J., Steventon, M.J., and Iversen, S.D., 1990, Differential effects of Dl and D2 agonists in MPTPtreated primates: Functional implications for Parkinson’s disease, Neurology 40:927–933.PubMedCrossRefGoogle Scholar
  6. Brozoski, T., Brown, R.M., Rosvold, H.E., and Goldman, P.S., 1979, Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey, Science 205:929–931.PubMedCrossRefGoogle Scholar
  7. Bums, R.S., Chiueh, C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., and Kopin, I.J., 1983, A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta substantia nigra by MPTP, Proc. Natl. Acad. Sci USA 80:4546–4550.CrossRefGoogle Scholar
  8. Clarke, C.E., Sandbrook, M.A., Mitchell, I.J., and Crossman, A.R., 1987, Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP), J. Neurol. Sci., 78:273–280.PubMedCrossRefGoogle Scholar
  9. Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Caine, E.D., Reichert, C.M., and Kopin, I.J., 1979, Chronic parkinsonism secondary to intravenous injection of meperidine analogues, Psychiat. Res. 1:249–254.CrossRefGoogle Scholar
  10. Diamond, A., 1990, Developmental time course in human and infant monkeys, and the neural bases of, inhibitory control in reaching, in: The Development and Neurol Bases of Higher Cognitive Functions Volume 608, Annals of the New York Academy of Sciences (A. Diamond, ed.), The New York Academy of Sciences, New York, pp. 637–677.Google Scholar
  11. Divac, I., Rosvold, H.E., and Szarcbart, M.K., 1967, Behavioral effects of selective ablation of the caudate nucleus, J. Comp. Physiol. Psycho!. 63:184–190.CrossRefGoogle Scholar
  12. Forno, L.S., 1982, Pathology of Parkinson’s disease, in: Movements Disorders (C.D. Marsden and S. Fahn, eds.), Butterworth, London, pp. 25–40.Google Scholar
  13. Fomo, L.S., 1986, The Lewy body in Parkinson’s disease, in: Advances in Neurology, Volume 45 (M.D. Yahr and K.J. Bergmann, eds.), Raven Press, New York, pp. 35–50.Google Scholar
  14. Forno, L.S., Langston, J.W., DeLanney, L.E., Irwin, I., and Ricaurte, G.A., 1986, Locus ceruleus lesions and eospinophilic inclusions in MPTP-treated monkeys, Ann. Neurol. 20:449–455.PubMedCrossRefGoogle Scholar
  15. Freedman, M., and Oscar-Berman, M., 1986, Selective delayed response deficits in Parkinson’s and Alzheimer’s disease, Arch. Neurol. 43:886–890.PubMedCrossRefGoogle Scholar
  16. German, D.C., Manaye, K., Smith, W.K., Woodward, D.J., and Saper, C.B., 1989, Midbrain dopaminergic cell loss in Parkinson’s disease: Computer visualization, Ann. Neurol. 26:507–514.PubMedCrossRefGoogle Scholar
  17. Goldman, P.S., and Rosvold, H.E., 1972, The effects of selective caudate lesions in juvenile rhesus monkeys, Brain Res. 43:53–66.PubMedCrossRefGoogle Scholar
  18. Homykiewicz, O., and Kish, S.J., 1986, Biochemical pathophysiology of Parkinson’s disease, in: Advances in Neurology,Volume 45 (M.D. Yahr, and K.J. Bergmann, eds.), Raven Press, New York, pp. 19–34.Google Scholar
  19. Jellinger, K., 1986, Overview of morphological changes in Parkinson’s disease, in:Advances in Neurology, Volume 45 (M.D. Yahr, and K.J. Bergmann, eds.), Raven Press, New York, pp. 1–18.Google Scholar
  20. Johnston, C.W., 1986, The neuropsychological evaluation of attention deficit disorder, Psychiatr. Ann. 16:47–51.Google Scholar
  21. Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I., 1983, Chronic parkinsonism in humans due a product of medperidineanalogue synthesis, Science 219:979–980.PubMedCrossRefGoogle Scholar
  22. Langston, J.W., Irwin, I., and Ricaurte, G.A., 1987, Neurotoxins, parkinsonism and Parkinson’s disease, Pharmac. Ther. 32:19–49.CrossRefGoogle Scholar
  23. Lau, H.C., Henricksen, L., and Bruhn, P., 1984, Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder, Arch. Neurol. 41:825–829.CrossRefGoogle Scholar
  24. Levin, B.E., Llabre, N.M., and Weiner, W.J., 1989, Cognitive impairments associated with early Parkinson’s disease, Neurology 39:557–561.PubMedCrossRefGoogle Scholar
  25. Mesulam, M.M., 1985, Principles of Behavioral Neurology,F.A. Davis, Philadelphia, p. 29.Google Scholar
  26. Pifl, Ch., Schingnitz, G., and Homykiewicz, O., 1988, The neurotoxin MPTP does not produce in the rhesus monkey, the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson’s disease, Neurosci. Lea. 92:228–233.CrossRefGoogle Scholar
  27. Roeltgen, M.G., Roeltgen, D.P., and Heilman, K.M., 1989, Unilateral motor impersistence and hemispatial neglect from a right striatal lesion, Neuropsychol. Neuropsychiatry Behay. Neurol. 2:125–135.Google Scholar
  28. Roeltgen, D.P., and Schneider, J.S., 1991, Chronic low-dose MPTP in non-human primates: A possible model for attention deficit disorder, J. Child Neurol. 6:582–589.Google Scholar
  29. Schneider, J.S., 1990, Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys, Brain Res. 534:25–36.PubMedCrossRefGoogle Scholar
  30. Schneider, J.S., and Kovelowski, C.J., 1990, Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys, Brain Res. 519:122–128.PubMedCrossRefGoogle Scholar
  31. Schneider, J.S., Yuwiler, A., and Markham, C.H., 1986, Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry, Exp. Neurol. 91:293–307.PubMedCrossRefGoogle Scholar
  32. Schneider, J.S., Yuwiler, A., and Markham, C.H., 1987, Selective loss of subpopulations of ventral metencephalic dopaminergic neurons in the monkey following exposure to MPTP, Brain Res. 411:144–150.PubMedCrossRefGoogle Scholar
  33. Schneider, J.S., Unguez, G., Yuwiler, A., Berg, S.C., and Markham, C.H., 1988, Deficits in operant behavior in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Brain 111:1265–1285.PubMedCrossRefGoogle Scholar
  34. Sharpe, M.H., 1990, Distractibility in early Parkinson’s disease, Cortex 26:239–246.PubMedGoogle Scholar
  35. Stem, Y., and Langston, J.W., 1985, Intellectual changes in patients with MPTP-induced parkinsonism, Neurology 35:1506–1509.PubMedCrossRefGoogle Scholar
  36. Stern, Y., Tetrud, J.W., Martin, W.R.W., Kutner, S.J., and Langston, J.W., 1990, Cognitive change following MPTP exposure, Neurology 40:261–264.PubMedCrossRefGoogle Scholar
  37. Taylor, A.E., Saint-Cyr, J.A., and Lang, A.E., 1986, Frontal lobe dysfunction in Parkinson’s disease, Brain 109:345–383.CrossRefGoogle Scholar
  38. Voeller, K.K.S., Alexander, A.W., Carter, R.L., and Heilman, K.M., 1989, Motor impersistence in children with attention deficit hyperactivity disorder decreases in response to treatment with methylphenidate, Neurology 39 (Suppl 1): 276.Google Scholar
  39. Wilson, J.S., and Wilson, J.A. 1986, Intracellular recordings in the caudate nucleus of normal and MPTP treated dogs, in: MPTP: A Neurotoxin Producing a Parkinsonian Syndrome (S.P. Markey, N. Castagnoli, A.J. Trevor, and I.J. Kopin, eds.), Academic Press, Orlando, pp. 695–699.Google Scholar
  40. Zamir, N., Skofitsch, G., Bannen, N.J., Helke, C.J., Kopin, I.J. and Jacobowitz, D.M., 1984, Primate model of Parkinson’s disease: Alterations in multiple opiod systems in the basal ganglia, Brain Res. 322:356–360.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • J. S. Schneider
    • 1
  1. 1.Center for Neurological Research of the Department of NeurologyHahnemann University School of MedicinePhiladelphiaUSA

Personalised recommendations